Aurobindo Pharma Reports 16% Revenue Growth, Completes Lannett Acquisition
The Indian pharmaceutical company posted Q1 FY2027 revenues of ₹9,150 crores while finalizing its strategic U.S. acquisition and preparing to launch a key respiratory product.
Strong Quarter Across Geographies
Aurobindo Pharma Limited reported consolidated revenues of ₹9,150 crores for the first quarter of fiscal year 2027, representing 16% year-on-year growth driven by "broad-based performance across our business areas" (earnings call, 2026-08-06). The company's formulation business contributed approximately 89% of revenues, growing 17% year-on-year to ₹8,101 crores.
Operating EBITDA stood at ₹1,924 crores with a margin of 21%, excluding a one-time loss of ₹43 crores related to lease receivable derecognition. CFO S. Subramanian highlighted that the company maintained its guidance for "double-digit revenue growth with EBITDA margin north of 21% and absolute EBITDA in excess of ₹8,000 crores" for the full fiscal year (earnings call, 2026-08-06).
Lannett Acquisition Completed, Advair Launch Imminent
A key milestone during the quarter was the completion of the Lannett acquisition following FTC approval. Swami Iyer, CEO of Aurobindo Pharma USA, announced that the company plans to "launch Advair any time in the month of August" (earnings call, 2026-08-06). The delay from earlier approval was attributed to inventory buildup requirements to ensure adequate market share positioning.
The Lannett deal strengthens Aurobindo's U.S. platform, particularly in complex generics and controlled substances. While Iyer noted that controlled substance quotas remain limited by regulatory constraints, he indicated Lannett has "been able to get a fair amount of quotas" and expects continued growth opportunities when other suppliers default or overall market quotas expand (earnings call, 2026-08-06).
Geographic Performance and Pipeline Progress
The U.S. business grew 8.1% year-on-year to $399 million, with 10 new product launches during the quarter, 9 ANDA filings, and 10 final approvals. European revenues reached €267 million, delivering 11% growth in constant currency terms.
Growth markets showed particularly strong momentum, with revenues increasing 38% year-on-year to ₹1,063 crores. Subramanian attributed this to expansion into new markets including Indonesia, China, and Canada, noting that "every country is doing well" rather than any single market driving extraordinary performance (earnings call, 2026-08-06).
Manufacturing Investments Bearing Fruit
Production at the company's China oral solid dosage facility doubled over the past 12 months, with supply now reaching both European and U.S. markets. The Pen-G plant achieved production capacity of 800-900 tonnes, effectively converting output into 6-APA and Amoxicillin with yields meeting expectations.
Subramanian emphasized that investments from the past decade are "approaching an important inflection point" as platforms transition from investment phase to "milestone monetization phase" (earnings call, 2026-08-06). The company maintained a net cash position of $42 million despite paying $85 million for share buybacks and $247 million for the Lannett acquisition.
Net profit after tax reached ₹1,032 crores for the quarter. R&D expenses amounted to ₹350 crores, or 4% of revenues, with management expecting "slightly lower development costs" ahead as multiple clinical studies reach advanced stages (earnings call, 2026-08-06).
This article was generated by MarginX from the earnings call on 2026-08-06. It is not investment advice.